News Headline Summary
Bristol Myers (BMY) says study data didn't warrant a phase III study
Reaction details:
- Co. shares dropped 0.6% in reaction to this headline, moving from USD 32.58 to USD 32.39; trades USD 32.45 last.
Print
18:39, 03 Dec 2012 -
US Equities
- Source:
Newswires
Subscribe Now to RANsquawk
Click here for a 1 week free trial
RANsquawk provides audio news and commentary for over 15,000
professional traders and brokers worldwide. Services include:
-
Real-time audio coverage from 0630 to 2130 London time
-
Teams of analysts covering equities, fixed income, FX and energy markets
-
Real-time scrolling news service
-
Daily and weekly pre-market research and calendars
-
Intra-day market update videos
-
Daily technical analysis